January 3, 2024 09:25 AM ESTUpdated January 4, 07:17 AM

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

HAYWARD, Calif. — After two decades at the highest R&D ranks of pharma, Roger Perlmutter has a blunt explanation for why drug development so often goes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Roger Perl­mut­ter lights up the bi­o­log­i­cal dark, build­ing a new phar­ma force in Eikon and its su­per­pow­ered mi­cro­scopes

Senior Biopharma Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roger Perlmutter lights up the biological dark, building a new pharma force in Eikon and its superpowered microscopes